Tool
Supplement comparison tool
Pick up to 4 knowledge base entries and compare their dosage, price, evidence strength and ratings side by side — you can save or share a link to your selection.
Add to comparison (2/4)
| Category | Leki | Leki |
| Evidence strength | Strong evidence | Strong evidence |
| Evidence Score | 4/5 | 5/5 |
| User rating | 4.3 (58) | 4.5 (58) |
| Typical dose | Usually started at 25 mg once daily, titrated gradually up to 50–100 mg three times daily with the first bite of each main meal — gradual titration significantly reduces the severity of gastrointestinal side effects | Start at 2.5 mg weekly, gradual escalation every 4 weeks to a maintenance dose of 5, 7.5, 10, 12.5, or a maximum of 15 mg weekly, depending on tolerance and treatment goal |
| Form | Oral tablets taken right before or with the first bite of a meal | Solution for subcutaneous injection in a single-use autoinjector (Mounjaro, Zepbound) |
| Average price | — | ok. 1000–1600 zł za opakowanie miesięczne, zależnie od dawki i apteki |
| Monthly cost | — | ok. 1000–1600 zł/miesiąc |
| Time to effects | The effect on post-meal glycemia is visible from essentially the first correctly timed dose (within hours), while improvement in longer-term markers like HbA1c usually takes 8–12 weeks of regular use at the target dose. | Reduced appetite is sometimes noticeable within the first few weeks, but meaningful, measurable weight loss develops gradually over several months, and the full effect assessed in SURMOUNT-1 was measured after 72 weeks (about 1.5 years) of regular treatment. |
| Who it's for | People with type 2 diabetes whose main problem is post-meal glycemia, assessed by a doctor | People with type 2 diabetes with inadequate glycemic control on other oral medications |